Imagine being able to quantify 92 proteins in just one microliter of sample without compromising either data quality or performance. Proseek® Multiplex does just this. It’s our exciting new solution for simultaneous measurement of human protein biomarkers. Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity when more and more assays are run simultaneously. Proseek Multiplex is a truly scalable immunoassay generating high quality data even in highly multiplexed format, see Data Package for more information.
Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) developed at Olink. PEA has a major advantage over conventional multiplex immunoassays in that only correctly matched antibody pairs give rise to a signal. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules. When binding to their correct targets, they give rise to new DNA amplicons each ID-barcoding their respective antigens. The amplicons are subsequently quantified by high throughput real-time PCR.
Proseek Multiplex can provide accurate quantification below picogram per milliliter levels even in small samples from, for example, needle biopsies or micro dialysis. This minimal sample consumption makes Proseek Multiplex especially suitable for retroactively mining precious biobanked serum samples for new multivariate biomarker signatures.
The opportunities are enormous for powerful analysis of multivariate biomarker patterns. Proseek Multiplex reactions are quantified by real-time PCR using the Fluidigm BioMark™ HD real-time PCR platform. The assay generates as much as 9,216 datapoints per run which can then be analyzed with Genex software, equipped with the user-friendly Proseek Multiplex data import wizard.
Proseek Multiplex offers:
Currently there are three kits available on the market: Proseek Multiplex Oncology I v2 96x96, Proseek Multiplex CVD I 96x96, and Proseek Multiplex Inflammation I 96x96. Each kit consists of a panel of 92 putative protein biomarkers targeting cancer, cardiovascular diseases, and inflammatory diseases respectively.